Mylan Cash Flow - Quarterly (NASDAQ:MYL)

Add to My Stocks
$40.8 $0.93 (2.23%) MYL stock closing price Mar 19, 2018 (Closing)

The Mylan cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Mylan profits, the balance sheet shows Mylan debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Mylan saw a cash impact of $12.8M from the issuance of MYL shares. The cash flow statement helps in the Mylan stock analysis by providing more information for evaluating changes in assets, liabilities and equities. The cash from operating activities for Mylan is $ 2017 Q3, which saw an increase from previous quarter.

View and download details of Mylan cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.28B836.7M415.5M1.52B1.05B600.5M297.1M1.03B691.4M
Net Increase (Decrease) in Assets Liabilities-541.2M-249.4M-228.6M-809.49M-160.3M-509.2M-407.7M-331.2M-295M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net379M70M199.6M853.7M749.1M223.5M177.2M459.9M307M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-125.3M-78.2M-27.3M-390.4M-239.5M-121M-51.8M-360.6M-205M
Acquisition Disposition of Subsidiaires-71.6M-71.6M-71.6M-6.48B-6.15B-943.3M--693.1M-
Increase (Decrease) in Investments----8.7M-7M-6.4M-2.6M-29M-29.7M
Other Cash Inflow (Outflow) from Investment Activities-546.2M-466.4M-65.2M-739.7M-683.4M-230.6M-105.6M-487M-404.6M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares12.8M8.9M5M13.8M11.1M6.8M3.6M30.2M92.8M
Issuance (Repayment) of Debt Securities-1.19B-770.9M-550M5.46B5.45B5.98B-1.03B26.69M
Increase (Decrease) in Bank & Other Borrowings-48.3M-42.7M-17.6M40.8M48.6M54.7M65.1M-329.2M-329.7M
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities-26.9M-26.1M-13.1M-165.9M-123.1M-119.9M-38.2M-122.1M-108.5M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash43.8M40.3M11.9M-8.3M15.1M9.7M12.4M-33.1M-37M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year1.24B225.5M291.3M349.96M375.05M662.05M380.51M557.14M484.2M
Cash & Equivalents at Year End614.9M612.8M723.8M998.8M1.26B6.36B1.2B1.24B587M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Mylan stock comparison chart provides an easy way to compare the stock price with peers along with details of Mylan stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Mylan saw a positive change in Net Change in Cash and Cash Equivalents of $-383.9M till 2017 Q3. Apart from the Mylan stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Mylan gained $1.57B cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: Mylan used $-743.1M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Mylan spent $-1.25B from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Mylan Cash Flow

FCF margin

Quarterly Cash Flow Statements For Mylan NV Peers

Allergan cash flow, Novartis cash flow, Pfizer cash flow, Teva Pharmaceutical cash flow